23
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Promoting apoptosis as a strategy for cancer drug discovery.

      Nature reviews. Cancer
      Animals, Antineoplastic Agents, therapeutic use, Apoptosis, drug effects, physiology, Apoptosis Regulatory Proteins, metabolism, Humans, Inhibitor of Apoptosis Proteins, chemistry, Membrane Glycoproteins, Neoplasms, drug therapy, Proto-Oncogene Proteins c-bcl-2, Proto-Oncogene Proteins c-mdm2, TNF-Related Apoptosis-Inducing Ligand, Tumor Necrosis Factor-alpha

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Apoptosis is deregulated in many cancers, making it difficult to kill tumours. Drugs that restore the normal apoptotic pathways have the potential for effectively treating cancers that depend on aberrations of the apoptotic pathway to stay alive. Apoptosis targets that are currently being explored for cancer drug discovery include the tumour-necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors, the BCL2 family of anti-apoptotic proteins, inhibitor of apoptosis (IAP) proteins and MDM2.

          Related collections

          Author and article information

          Comments

          Comment on this article